TRVI: Total Utang marang Modal Trevi Therapeutics, Inc.

Logo perusahaan publik Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics (TRVI) currently lacks pricing power and relies on external capital. The total liabilities-to-equity ratio visualizes this dependency, where the value of 0.00 shows the current level of debt load. This situation is driven by management's focus on neurological drugs and strict compliance with environmental standards for chemical waste disposal in laboratories.

TRVI - Total Utang marang Modal Trevi Therapeutics, Inc. ing rentang 04.07.2022 - 31.10.2026

Rincian metrik lan analitis perusahaan Trevi Corp (TRVI)

- rega lan prakiraan konsensus rega:
Bagan rega Trevi Therapeutics, Inc.|TRVI - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Kapitalisasi pasar Trevi Therapeutics|TRVI - Total Nilai Perusahaan
- indikator kapitalisasi buku:
Nilai Akuntansi saben Saham Trevi Therapeutics|TRVI - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku trevitherapeutics.com|TRVI - Nilai Agregat Aset
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Trevi Therapeutics|TRVI - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Trevi Therapeutics|TRVI - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Trevi Therapeutics|TRVI - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Trevi Therapeutics|Indikator likuiditas cepet trevitherapeutics.com
- statistik bathi lan rasio pasar:
TRVI - Bathi resik perusahaan
Pambiji fundamental:TRVI, Trevi Therapeutics, Inc.
Barang utama trevitherapeutics.com

The financial stability of Trevi Therapeutics (TRVI) is based on the control of its debt load. The total debt-to-equity ratio measures the proportion of borrowed funds within the asset structure, determining the risk of insolvency. An increase in this metric signals excessive leverage. Low reliance on loans allows the company to confidently develop unique cough medications. An optimal capital balance confirms the fair market value of the business.

Analisis pesaing Trevi Therapeutics

Utang marang Ekuitas Biogen|Rasio Utang marang Ekuitas NBIX (Neurocrine)|Total Utang marang Modal RGC|AXSM - Utang marang Modal|ACADIA Pharmaceuticals - Rasio Total Utang marang Ekuitas|Total Utang marang Modal xenon-pharma.com XENE|VKTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi SUPN (Supernus Pharmaceuticals, Inc.)|Catalyst Pharmaceuticals Inc (CPRX) - Utang marang Ekuitas|Utang marang Modal Denali Corp (DNLI)|Rasio Total Utang marang Ekuitas HRMY|BHVN (biohavenpharma.com) - Utang Agregat marang Modal|Utang marang Ekuitas Amylyx Pharmaceuticals, Inc. (AMLX)|PRAX (Praxis Precision Medicines Inc) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AVXL (Anavex Corp)|CeriBell EEG (CBLL) - Utang marang Modal|PRTA: Rasio Total Utang marang Ekuitas|ALEC: Utang marang Ekuitas|ANNX: Total Utang marang Modal|OMER - Koefisien Total Utang marang Modal|Rasio Total Utang marang Ekuitas NGNE|ACIU: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas VYGR (Voyager Therapeutics)|Utang Agregat marang Modal NMRA|Total Utang marang Modal SCLX (Scilex)|Rasio Kabeh Utang marang Dana Pribadi TVGN|Alpha Cognition Corp - Total Utang marang Modal|Utang marang Modal Cognition Therapeutics Inc.|Inhibikase Therapeutics (IKT) - Utang marang Ekuitas|cassavasciences.com - Rasio Kabeh Utang marang Dana Pribadi|ASRT (Assertio Holdings) - Total Utang marang Modal|Total Utang marang Modal Coya|Utang marang Ekuitas Vistagen Therapeutics (VTGN)|OVID: Utang Agregat marang Ekuitas|Total Utang marang Modal ABOS (Acumen Pharmaceuticals)|cervomed.com (CRVO) - Utang marang Modal|ATHE: Rasio Total Utang marang Ekuitas|CLNN - Total Utang marang Modal|PEPG (pepgen.com) - Rasio Total Utang marang Ekuitas|JUNS: Utang Agregat marang Modal|RLMD (Relmada Therapeutics) - Total Utang marang Modal|annovisbio.com (ANVS) - Koefisien Total Utang marang Modal|Total Utang marang Modal GRCE|Rasio Total Utang marang Ekuitas Firefly Neuroscience, Inc. AIFF|Utang marang Ekuitas Klotho Neurosciences KLTO|Koefisien Total Utang marang Modal NeuroSense Therapeutics Ltd (NRSN)|RVPH: Rasio Total Utang marang Ekuitas|MetaVia Inc - Utang Agregat marang Modal|NeurAxis (NRXS) - Utang marang Ekuitas|Helius Medical Technologies - Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas PASG|Utang marang Ekuitas NEUP|Total Utang marang Modal NERV|Koefisien Total Utang marang Modal athira.com|Utang marang Ekuitas Addex Therapeutics Ltd ADXN|ALZN: Rasio Utang marang Ekuitas|Cyclerion - Total Utang marang Modal|Utang marang Modal Protagenic Therapeutics|KTTA (pasitheaclinics.com) - Rasio Total Utang marang Ekuitas|Cortigent (CRGT) - Total Utang marang Modal|Utang marang Ekuitas Avenue Therapeutics, Inc.|BCLI: Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Cara Therapeutics, Inc (CARA)|CHRO - Utang marang Modal|Eliem Therapeutics Inc. - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal ITCI (Intra-Cellular Therapies Inc.)|LBPH - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi MRNS (Marinus Pharmaceuticals Inc)|NKGN: Total Utang marang Modal|Utang marang Modal NeuroBo Pharma (NRBO)|Rasio Total Utang marang Ekuitas SAGE|Utang marang Ekuitas SNPX|Total Utang marang Modal TRVN|Koefisien Total Utang marang Modal vigilneuro.com|Anew Medical - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CERE